Abnormal platelet function may complicate the assessment and treatment of continuing blood loss, hypotension, and coagulation disorders during adult donor care. Antiplatelet drugs, such as aspirin, nonsteroidal anti-inflammatory drugs, clopidogrel (Plavix), ticlopidine (Ticlid), prasugrel (Effient), abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat) are commonly prescribed for older patients. These medications may be part of home therapy or may be given during acute cardiac or cerebrovascular crises that may lead to brain death and organ donation. This discussion reviews normal platelet formation and function, drug actions, methods to evaluate medication effects, pharmacological characteristics, treatment recommendations for platelet transfusion, and risks attendant with those infusions.
Get full access to this article
View all access options for this article.
References
1.
PownerDJReichHS. Regulation of coagulation abnormalities and temperature in organ donors. Prog Transplant.2000;10(3): 146–153.
2.
PownerDJ. Thromboelastography during adult donor care. Prog Transplant.2010;20(2):163–168.
3.
WeiAHSchoenwaelderSMAndrewsRKJacksonSP. New insights into the haemostatic function of platelets. Br J Haematol2009;147(4):415–430.
4.
BattinelliEMHartwigJHItalianoJE. Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol.2007;14(5):419–426.
5.
KaushanskyK. Determinants of platelet number and regulation of thrombopoiesis. Hematol Am Soc Hematol Educ Program.2009:147–152.
6.
KaushanskyK. The molecular mechanisms that control thrombopoiesis. J Clin Invest.2005;115(12):3339–3347.
7.
SpiessBD. Platelet transfusions: The science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol.2010;24(1):65–83.
8.
PownerDJHootsWK. Thrombocytosis in the NICU. Neurocrit Care.2008;8(3):471–475.
9.
CramerEMNorolFGuichardJ. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood.1997;89(7):2336–2346.
10.
ItalianoJELecinePShivdasaniRAHartwigJH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol.1999;147(6):1299–1312.
11.
WhiteJGGerrardJM. The ultrastructure of defective human platelets. Mol Cell Biochem.1978;21 (2): 109–128.
12.
MaynardDMHeijnenHFHorneMKWhiteJGGahlWA. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost.2007;5(9):1945–1955.
13.
WhiteJG. Electron opaque structures in human platelets: Which are or are not dense bodies?Platelets.2008;19(6):455–466.
14.
BeckerRCSmythS. The evolution of platelet-directed pharmacotherapy. J Throm Haemost.2009;7(suppl 1):266–271.
15.
NielsenHLKristensenSDThygesenSS. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res.2008;123(2):267–273.
16.
CapodannoDAngiolilloDJ. Platelet monitoring for PCI: Which test is the one to choose?Hamostaseologie.2009;29(4):376–380.
17.
HaywardCPHarrisonPCattaneoMOrtelTLRaoAK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost.2006;4(2):312–319.
18.
DaviGPatronoC. Platelet activation and atherothrombosis. N Engl J Med.2007;357(24):2482–2494.
19.
PatronoCCollerBFitzGeraldGA. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest.2004:126(3 suppl):234S–264S.
20.
CalverleyDCRothGJ. Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. Hematol Oncol Clin North Am.1998;12(6):1231–1249.
21.
SchaferAI. Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol.1995;35(3):209–219.
22.
RileyABTafreshiMJHaberSL. Prasugrel: A novel antiplatelet agent. Am J Health-Syst Pharm.2008;65(11): 1019–1028.
23.
CattaneoM. New P2Y(12) Inhibitors. Circulation.2010;121(1): 171–179.
24.
ChunROrserBAMadanM. Platelet glycoprotein IIb/IIIa inhibitors: Overview and implications for the anesthesiologist. Anesth Analg.2002;95(4):879–888.
25.
SchrörKWeberAA, Comparative pharmacology of GP IIb/IIIa antagonsists. J Thromb Thrombolysis.2003;15(2):71–80.
26.
ReiterRJilma-StohlawetzPHorvathMJilmaB. Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide. Transfusion.2005;45(3):420–426.
27.
LiYFSpencerFABeckerRC. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition. Am Heart J.2002;143(4):725–732.
28.
ChenATeruyaJ. Global hemostasis testing thromboelastography: Old technology, new applications. Clin Lab Med.2009; 29(2):391–407.
29.
CollyerTCGrayDJSandhuRBerridgeJLyonsG. Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography Platelet Mapping. Br J Anaesth.2009;102(4):492–498.
30.
AkinsPTGuppyKHSahrakarKHawkMW. Slippery platelet syndromes in subdural hematoma. Neurocrit Care.2010;12(3):375–381.
31.
PownerDJHartwellEAHootsWK. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery.2005;57(5):823–831.
32.
BarlettaJFCooperBOhlingerMJ. Adverse drug events associated with disorders of coagulation. Crit Care Med.2010; 38(suppl):S198–S218.
33.
RiceTWWheelerAP. Coagulopathy in critically ill patients: Part 1: Platelet disorders. Chest.2009;136(6):1622–1630.
34.
BensonABMossMSillimanCC. Transfusion-related acute lung injury (TRALI): A clinical review with emphasis on the critically ill. Br J Haematol.2009;147(4):431–443.
